Gain-of-function mutations in Pcsk9 are linked to familial hypercholesterolemia and the inhibition of PCSK9 is emerging as a novel strategy for the treatment of hypercholesterolemia (32, 33). Here, PCSK9 is linked to familial hypercholesterolemia.